Literature DB >> 18509249

Expression of the WASP verprolin-homologues (WAVE members) in human breast cancer.

H S Fernando1, S R Davies, A Chhabra, G Watkins, A Douglas-Jones, H Kynaston, R E Mansel, W G Jiang.   

Abstract

BACKGROUND: The WASP family proteins have been indicated to play a vital role in the formation of membrane protrusions required for cell locomotion. WAVE proteins are an important subfamily that also plays a crucial role in actin polymerisation, which is vital to cell migration. However, not much is known about the clinical significance of this subfamily in cancers. We report, for the first time, the expression of the WAVE molecules, at protein and mRNA levels, in human breast cancer.
MATERIALS AND METHODS: The expression of the 3 WAVE molecules at the mRNA and protein levels in a cohort of 122 human breast cancers and 32 normal breast tissues were analysed and correlated with the patients' pathological and clinical information as well as outcome (120 months follow-up).
RESULTS: All 3 WAVE molecules were detected in mammary tissues. WAVE2 transcripts were expressed in high levels in all breast tumours. Over-expression of WAVE2 was seen in node-positive cases as well as in moderately and poorly differentiated tumours. Also, high levels of WAVE2 expression were associated with death due to disease (p = 0.02) at follow-up. No distinct associations were found between the WAVE1 and WAVE3 transcripts and the breast cancer cells. 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18509249     DOI: 10.1159/000136157

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  13 in total

1.  Clinical significance and expression of the PRSS3 and Wiskott-Aldrich syndrome protein family verprolin-homologous protein 1 for the early detection of epithelial ovarian cancer.

Authors:  Sima Azizmohammadi; Aghdas Safari; Mehri Seifoleslami; Rahman Ghaffarzadegan Rabati; Mohsen Mohammadi; Hamid Yahaghi; Susan Azizmohammadi
Journal:  Tumour Biol       Date:  2015-12-10

Review 2.  Nucleating actin for invasion.

Authors:  Alexander Nürnberg; Thomas Kitzing; Robert Grosse
Journal:  Nat Rev Cancer       Date:  2011-02-10       Impact factor: 60.716

Review 3.  Filopodia and adhesion in cancer cell motility.

Authors:  Antti Arjonen; Riina Kaukonen; Johanna Ivaska
Journal:  Cell Adh Migr       Date:  2011 Sep-Oct       Impact factor: 3.405

4.  WAVE3, an actin remodeling protein, is regulated by the metastasis suppressor microRNA, miR-31, during the invasion-metastasis cascade.

Authors:  Khalid Sossey-Alaoui; Erinn Downs-Kelly; Mitali Das; Lahoucine Izem; Raymond Tubbs; Edward F Plow
Journal:  Int J Cancer       Date:  2011-03-22       Impact factor: 7.396

5.  Crk and ABI1: binary molecular switches that regulate abl tyrosine kinase and signaling to the cytoskeleton.

Authors:  Sajjad Hossain; Patrycja M Dubielecka; Aleksander F Sikorski; Raymond B Birge; Leszek Kotula
Journal:  Genes Cancer       Date:  2012-05

Review 6.  Elucidating the molecular signaling pathways of WAVE3.

Authors:  Urna Kansakar; Wei Wang; Vesna Markovic; Khalid Sossey-Alaoui
Journal:  Ann Transl Med       Date:  2020-07

Review 7.  Actin binding proteins: their ups and downs in metastatic life.

Authors:  Stephane R Gross
Journal:  Cell Adh Migr       Date:  2013-01-09       Impact factor: 3.405

Review 8.  Endocytosis and signaling: cell logistics shape the eukaryotic cell plan.

Authors:  Sara Sigismund; Stefano Confalonieri; Andrea Ciliberto; Simona Polo; Giorgio Scita; Pier Paolo Di Fiore
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 37.312

Review 9.  The WASP and WAVE family proteins.

Authors:  Shusaku Kurisu; Tadaomi Takenawa
Journal:  Genome Biol       Date:  2009-06-15       Impact factor: 13.583

10.  Scar/WAVE3 contributes to motility and plasticity of lamellipodial dynamics but not invasion in three dimensions.

Authors:  Heather J Spence; Paul Timpson; Hao Ran Tang; Robert H Insall; Laura M Machesky
Journal:  Biochem J       Date:  2012-11-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.